April 23, 2024
Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the […]
April 22, 2024
TOPLINE: A new, international, 5-year trial of the immunotherapy drug pembrolizumab (Keytruda) contained the largest patient contingent from the United Kingdom and Europe. As the first […]
April 22, 2024
There have been many attempts to use immunotherapy to improve outcomes in pancreatic cancer, but they haven’t worked out. The trials, however, have focused on adding […]
April 22, 2024
The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following tumor resection in patients with anaplastic lymphoma kinase (ALK)–positive […]
April 19, 2024
TOPLINE: A new three-phase screening protocol that incorporates a PSA test, a four-kallikrein panel, and an MRI scan appears to improve the prostate cancer detection rate […]
April 19, 2024
A study conducted in the United States showed that many individuals undergo lung cancer screening despite having a higher likelihood of experiencing harm rather than benefit. […]
April 18, 2024
TOPLINE: Late-stage cancer incidence may be a suitable alternative endpoint to cancer-specific mortality in lung and ovarian cancer screening trials, but not in breast, colorectal, or […]
April 18, 2024
Medicare reimbursement for common breast cancer surgeries decreased significantly over the past two decades, and the resulting shortage of funds could affect quality of care and […]
April 18, 2024
Colorectal cancer (CRC) is a major public health issue, with over 43,000 new cases and nearly 17,700 deaths annually in France. The overall survival rate is […]